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Feline immunodeficiency virus (FIV) gene orf-A, also designated orf-2, encodes a 77 amino acid accessory protein reported to be critical
for efficient viral replication in vitro and in vivo and previously implicated to encode a Tat protein for FIV. However, recent studies have
shown Orf-A to be important in the late steps of the FIV life cycle involved in virion formation and in early steps involved in virus infectivity
(J. Virol. 77 (2003) 8819). The present study reports that expression of a GFP-Orf-A fusion protein in both primate and feline cell lines
results in nuclear localization of this FIV accessory protein. Moreover, a nuclear localization signal (NLS) critical for nuclear import was
mapped to amino acid residues 43 through 53 of Orf-A. Lastly, transient expression of GFP-Orf-A in cells induced an arrest at the second gap
(G2) of the cell cycle. Our findings reveal that Orf-A is a nuclear protein that expresses properties similar to those reported for human
immunodeficiency virus-1 (HIV-1)-encoded Vpr.
D 2004 Elsevier Inc. All rights reserved.Keywords: FIV; Amino acid; HIVIntroduction
Feline immunodeficiency virus (FIV) is a member of the
lentivirus subfamily of retroviruses that naturally infects
domestic cats and causes an immunodeficiency syndrome
similar to that associated with human immunodeficiency
virus-1 (HIV-1) infection in humans. Decreased CD4 T-cell
concentrations, inverted CD4/CD8 T-cell ratio, and en-
hanced susceptibility to infectious agents are hallmark
characteristics of infection with these two viruses (Bend-
inelli et al., 1995). Similar to HIV-1 and other lentiviruses,
the FIV genome encodes three large open reading frames,
gag, pol, and env, that encode for structural and enzymatic
proteins (Talbott et al., 1989). HIV-1 encodes six additional
small open reading frames that express regulatory and
accessory proteins: vif, rev, tat, vpr, vpu, and nef. However,
the FIV genome contains only three additional open reading0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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eesparger@ucdavis.edu (E.E. Sparger).frames, two of which include rev, that encodes a viral post-
transcriptional regulatory protein and vif that encodes an
accessory protein necessary for viral infectivity. The prima-
ry function of the third gene designated orf-A (also orf-2)
remains unclear. Similarities in genomic organization and
immunological dysfunctions observed for FIV and HIV-1
validate the use of FIV as an animal model for development
of HIV-1 vaccines and anti-viral therapies (Bendinelli et al.,
1995). However, a thorough functional analysis of viral
accessory and regulatory genes shared between the primate,
and feline lentiviruses will be necessary to facilitate the use
of this feline HIV animal model.
FIVorf-A is a small 234 nucleotide (nt) gene that encodes a
putative 77 amino acid protein with a molecular weight of 8–
9 kDa. The orf-A gene product is necessary for efficient viral
replication in interleukin-2 (IL-2)-dependent feline lymphoid
cell lines and peripheral blood mononuclear cells (PBMC)
(Dean et al., 1999; Waters et al., 1996), and is also critical for
efficient viral replication in vivo (Dean et al., 1999; Inoshima
et al., 1996; Pistello et al., 2002). Our recent studies demon-
strated that the orf-A gene product was important for the late
steps of the FIV viral life cycle involved in virion formation
and was also critical for virion infectivity (Gemeniano et al.,
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functions analogous to those expressed by HIV-1 Vpr, Vpu,
or Nef, a possibility that has not been previously examined.
To further explore the function of this FIVaccessory gene, the
subcellular location of Orf-A expression was evaluated in
both a simian and a feline cell line. These studies revealed
nuclear localization of Orf-A in cells transfected with a green
fluorescent protein (GFP)-Orf-A expression plasmid, as well
as identification of an Orf-A-encoded nuclear localization
signal (NLS). Furthermore, we demonstrate that transient
expression of FIV Orf-A induces G2 arrest of transfected
cells.Results
Localization of FIV Orf-A
To extend our previous studies and further examine the
primary function of orf-A, we investigated the subcellular
localization of FIV Orf-A by transfection of both African
green monkey kidney (COS-7) cells and feline Crandell
feline kidney (CrFK) cells with either WT or mutant
pEGFP-OrfA plasmids (Fig. 1A). Transfected cells were
examined for subcellular distribution of green fluorescence
produced by GFP-Orf-A proteins and for blue fluorescence
associated with a nuclear (DAPI) stain using a fluorescence
microscope. A whole-cell green fluorescence pattern was
observed in COS-7 cells transfected with GFP expression
plasmid (pEGFP-C1) alone (Fig. 2D). In contrast, green
fluorescence was limited to the nucleus of COS-7 cells
transfected with pEGFP-Orf-A plasmid indicating that
GFP-Orf-A expression was restricted to the nucleus (Fig.Fig. 1. Mapping of the nuclear localization signal of FIV Orf-A and alignment of
acid sequence of full-length FIV-pPPR Orf-A (WT Orf-A) is shown at the top (A).
are indicated. Deletion mutants and a point mutant with alanine substitutions are
residues. An introduced stop codon is represented by an asterisk (*). GFP e
characterized by GFP fused to the N terminus of wild-type and mutant Orf-A sequ
1SF2 Vpr were manually aligned by centering sequences on the putative nuclear e
Gaps (– ) were introduced to optimize the alignment of identical amino acids and
sequences. HIV-1 Vpr has been shown to encode two NLSs (amino acids critica
leucine-rich domain with significant homology to the NES expressed by the Vpr2G). Similar subcellular distribution of GFP-Orf-A and DAPI
fluorescence further supported the nuclear localization of
Orf-A (Figs. 2G and H).
Careful examination of the C terminus of FIV Orf-A
revealed a series of basic amino acids (lysines and arginines)
spanning residues 44–53 (RLRFRKPKSK) suggestive of a
canonical NLS (Fig. 1). Upon demonstrating nuclear locali-
zation of GFP-Orf-A, Orf-A mutant proteins, GFP-Orf-
Atrp43stop, GFP-Orf-A43–77, and GFP-Orf-A54–77 were
assayed for subcellular localization to determine if residues
44–53 represent an NLS. Localization of GFP-Orf-Atrp43-
stop, a truncated form of Orf-A that includes the N-terminal
42 amino acids of Orf-A, was characterized by a whole-cell
distribution of green fluorescence (Figs. 2J and K) similar to
that observed with COS-7 cells transfected with pEGFP-C1.
However, expression of GFP-Orf-A43–77, a truncated pro-
tein encoding the putative NLS followed by the remaining 24
C-terminal amino acids of Orf-A, was restricted to the nucleus
suggesting that a nuclear localization signal was encoded
within amino acids 43–77 of Orf-A (Figs. 2P and Q). The
generalized diffuse whole-cell staining pattern observed with
the GFP-Orf-A54–77, a truncated protein encoding the 25 C-
terminal amino acids of Orf-A, indicated that the FIV Orf-A
NLS does not reside in the region spanning residues 54–77
(Figs. 2S and T). Localization experiments testing these three
fusion proteins further confirmed the nuclear localization of
WT Orf-A and mapped an NLS to residues 43–53.
Localization experiments also examined GFP-Orf-A-L-
A, a mutant characterized by modification of six leucine
residues to alanines within the leucine-rich domain imme-
diately upstream of the NLS mapped for Orf-A (Fig. 1A).
This leucine-rich domain (residues 34–42) bears a striking
homology to a region encoded by HIV-1 Vpr (residues 60–amino acid sequences for FIV-pPPR Orf-A and HIV-1SF2 Vpr. The amino
Putative functional domains and nuclear localization signal (NLS) of Orf-A
shown below the WT sequence where dashes (– ) represent unchanged WT
xpression plasmids were created to generate GFP-Orf-A fusion proteins
ences. Partial amino acid sequences encoded by FIV-pPPR Orf-A and HIV-
xport signal (NES) and nuclear localization signal (NLS) of FIV Orf-A (B).
amino acids with similar properties (indicated in bold) between the aligned
l for nuclear localization are underlined). Note that FIV Orf-A encodes a
proteins of HIV-1SF2.
Fig. 2. Subcellular localization of GFP-OrfA. COS-7 and CrFK cells were mock transfected (A–C) or transfected with pEGFP-C1 (D–F), pEGFP-Orf-A
(G–I), pEGFP-Orf-A-trp43stop (J–L), pEGFP-Orf-A-L-A (M–O), pEGFP-Orf-A43–77 (P–R), and pEGFP-Orf-A54–77 (S–U). Localization was determined
by GFP (A, C–D, F–G, I– J, L–M, O–P, R–S, and U) and DAPI fluorescence (B, E, H, K, N, Q, and T) detected with the Nikon Eclipse E800 microscope.
CrFK cells were counter-stained with propidium iodide.
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al., 2001) (Fig. 1B). As predicted, GFP-Orf-A-L-A localized
to the nucleus in COS-7 cells when assayed by fluorescence
microscopy (Figs. 2M and N). Vacuolar spaces were also
observed in the nuclei of cells expressing GFP-Orf-A-L-A.
Lastly, because the above experiments were performed in
primate cells, it was important to demonstrate that the
subcellular distribution of these fusion proteins were similar
in the feline CrFK cell line (Figs. 2C, F, I, L, O, R, and U).
Taken together, these results are the first demonstration that
Orf-A is a FIV-encoded protein targeted to the nucleus and
encodes a canonical nuclear localization signal consisting of
a single stretch of basic amino acid residues.Expression of GFP-Orf-A and mutant proteins of the
predicted size
Immunoblot analysis was performed on GFP immuno-
precipitates from transfected COS-7 cell extracts to assess
the size and stability of WT and mutant GFP-Orf-A fusion
proteins. Stable expression of GFP-Orf-A (WT and mutant)
fusion proteins was confirmed by immunoprecipitation of
proteins from cell extracts and Western blot analysis using
an anti-GFP antibody (Fig. 3A). GFP is a 239 amino acid
protein characterized by a protein band migrating at 27 kDa
(Fig. 3A, lane 2). Full-length orf-A encodes a 77 amino acid
protein with a predicted molecular weight of 8–9 kDa. As
Fig. 3. Expression of GFP-Orf-A proteins by Western blot analysis. GFP-Orf-A fusion proteins were immunoprecipitated from COS-7 cells with mouse
monoclonal anti-GFP antibody 48 h after a mock transfection or transfection with either pEGFP-C1, pEGFP-Orf-A, pEGFP-Orf-A-L-A, pEGFP-Orf-
Atrp43stop, pEGFP-Orf-A43–77, and pEGFP-Orf-A54–77 as described in Materials and methods. Immunoprecipitated proteins were separated on a 12%
SDS-PAGE, transferred onto a nitrocellulose membrane, and analyzed for GFP-Orf-A proteins by Western blot analysis using the same anti-GFP antibody (A)
or a rabbit polyclonal FIV Orf-A-specific antibody (B). The positions of GFP-Orf-A and GFP are indicated on the left side of the figure.
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ing at 35 kDa (Fig. 3A, lane 3). GFP-Orf-A-L-A, GFP-Orf-
Atrp43stop, GFP-Orf-A43–77, and GFP-Orf-A54–77 were
characterized by protein bands migrating at 35, 30, 29, and
28 kDa, respectively (Fig. 3, lanes 4–7). Expression of Orf-
A from these fusion proteins was also examined by probing
GFP immunoprecipitates with a polyclonal antibody specif-
ic to Orf-A (Fig. 3B). As expected, Orf-A antibody recog-
nized GFP-Orf-A, Orf-A-L-A, and GFP-Orf-Atrp43stop
GFP fusion proteins (Fig. 3B, lanes 3–5). However, the
absence of bands specific for GFP-Orf-A43–77 or GFP-
Orf-A54–77 (Fig. 3B, lanes 6–7) suggested that epitopes
located in the C terminus were not recognized by this
polyclonal anti-Orf-A antibody. Smaller molecular weight
bands were observed in GFP-Orf-A immunoprecipitates
probed with either GFP or Orf-A antibody (Figs. 3A and
B) and most likely represent degradation products of the
GFP-Orf-A fusion proteins.
Orf-A induces a cell cycle arrest
On the basis of our current findings demonstrating
nuclear localization of GFP-Orf-A, we assayed Orf-A for
properties previously reported for another HIV-1 nuclear
protein, Vpr. HIV-1-encoded Vpr localizes to the nucleus
(Lu et al., 1993) and induces both apoptosis (Stewart et al.,
1997) and G2 cell cycle arrest (Jowett et al., 1995; Rogel et
al., 1995). To determine whether Orf-A is capable of
inducing arrest at G2 of the cell cycle, we examined the
cell cycle profiles of COS-7 cells post-transfection with
pEGFP-Orf-A, pEGFP-Orf-Atrp43stop, and pEGFP-C1
(control). For these experiments, DNA synthesis in S-phase
was assayed by measuring BrdU incorporation with PE-
labeled anti-BrdU antibody and 7-AAD staining using flow
cytometry. The percentage of GFP-Orf-A-expressing cells
in G0/G1, S, and G2 + M phase was determined by gating
on the GFP-positive cell population. As shown in Figs. 4A
and B, the cell cycle profiles of cells expressing GFP alone
were as follows: G0/G1, 42%; S phase, 19%; G2 + M, 39%.However, GFP-Orf-A expression produced a cell cycle
profile characterized by 16% of the cells in G0/G1 phase,
9% of cells in S phase, and 69% of cells in G2 + M. Based
on these data, (G2 + M)/(G0/G1) ratio for cells expressing
GFP-Orf-A (4.3) was 4.8-fold higher compared with cells
expressing GFP alone (0.9) (Fig. 4A). The larger proportion
of cells expressing GFP-Orf-A at G2 + M phase suggests
that Orf-A induced a block at G2 of the cell cycle. Cell cycle
profiles determined for cells expressing GFP-OrfAtrp43stop
revealed that 28% of GFP-positive cells were in G0/G1
phase, 24% in S phase, and 48% in G2 + M phase. The
(G2 + M)/(G0/G1) ratio (1.7) measured for mutant GFP-Orf-
Atrp43stop-expressing cells was only 1.8-fold higher than
the ratio found with cells expressing GFP alone. The smaller
effect on cell cycle associated with expression of truncated
Orf-A (GFP-Orf-Atrp43stop) suggests that the N-terminal
half of the Orf-A protein may contribute to this function but
is not sufficient for the G2 arrest observed with WT Orf-A
expression. Analysis of three different experiments revealed
similar results showing (G2 + M)/(G0/G1) ratios ranging
from 0.87 to 1.1, 2.8 to 4.3, and 1.7 to 2.3 for GFP, GFP-
Orf-A, and GFP-OrfAtrp43stop, respectively (Fig. 4C).
Taken together, our results suggest that expression of WT
Orf-A arrests cells into G2 + M phase of the cell cycle and
encodes a protein with functions similar to those described
for HIV-1-encoded Vpr.Discussion
Attempts to detect Orf-A expression in FIV-infected cells
have been unsuccessful, and a recent report revealed very
low expression of Orf-A in mammalian cells from either a
mammalian expression plasmid or retroviral vector, possibly
due to protein instability (Chatterji et al., 2002). We also
experienced difficulties with detection of expression of Orf-
A from various mammalian expression vectors designed to
express native proteins without a fused tag or a protein with
a small epitope, and furthermore observed a reduced half-
Fig. 4. Transient expression of FIV Orf-A expression results in G2 arrest in
transfected cells. COS-7 cells transfected with either pEGFP-Orf-A,
pEGFP-Orf-Atrp43stop, or pEGFP-C1 (negative control) were labeled
with BrdU and stained with 7AAD and then analyzed for fluorescence by
FACScan using the CellQuest program. Data for each sample from a
representative experiment was normalized for cell number. Cell cycle
distribution was determined based on BrDU and 7AAD incorporation of the
green fluorescent population only. The (G2 + M)/(G0/G1) ratio calculated
for each transfection is shown below each histogram (A). Cell cycle
distribution of GFP-positive cells for each transfection from the same
representative experiment is also shown in a graph (B). The mean (G2 +M)/
(G0/G1) ratio observed for cells transfected with either pEGFP-Orf-A,
pEGFP-Orf-Atrp43stop, or pEGFP-C1 were calculated from three trans-
fection studies (C).
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extracellular surface and transmembrane domains of the
human CD8 protein (data not shown). However, in our
previous studies (Gemeniano et al., 2003), experiments
involving cotransfection of pEGFP-Orf-A with an orf-
A-deleted FIV provirus confirmed the functional activity of
GFP-Orf-A by demonstrating the ability of this protein to
fully complement the defective virus particle formation
associated with this FIV orf-A deletion mutant. In thepresent study, we demonstrate stable expression of this
same GFP-Orf-A fusion protein, as well as other GFP fusion
proteins encoding Orf-A mutants, by Western blot analysis
and fluorescent microscopy of cells transfected with GFP-
Orf-A expression vectors (Figs. 2 and 3). Moreover, we
show that expression of this functional GFP-Orf-A protein
is predominately localized to the nucleus of cells by assay of
both simian and feline cell lines.
Assessment of Orf-A sequence suggested a single stretch
of basic amino acids spanning residues 44–53 (RLRFRKP
KSK) as a candidate NLS. Therefore, subcellular distribution
of GFP-Orf-A and specific deletion mutants of Orf-A fused to
GFP (Fig. 2) was examined by fluorescence microscopy to
verify that residues 44–53 function as an NLS for Orf-A.
Observations showing restriction of fluorescence to nuclei of
cells expressing WT GFP-Orf-A, GFP-Orf-A43–77, and
GFP-Orf-A-L-A, in contrast to a whole-cell distribution of
fluorescence for mutants GFP-Orf-Atrp43stop and GFP-Orf-
A54–77 or GFP alone, demonstrate that the stretch of lysine
and arginine residues spanning amino acids 44–53 is re-
quired for nuclear localization of GFP-Orf-A. Moreover,
these observations were consistent for Orf-A subcellular
localization studies in both COS-7 and feline CrFK cells
(Fig. 2). These findings represent the first report that
describes the FIV Orf-A accessory protein as a nuclear
protein and the mapping of an NLS within FIV Orf-A.
However, examination of additional Orf-A mutants will be
necessary to investigate the possibility that other residues
located in the C terminus of this protein may contribute to
Orf-A nuclear localization. Future studies examining Orf-A
fused to smaller or different tags, as well as tags on the
carboxy terminus of Orf-A, and Orf-A proteins from other
FIV isolates, are also warranted to further characterize sub-
cellular distribution of this FIV accessory protein.
Data from our previous studies (Gemeniano et al., 2003;
Sparger et al., 1992) and other reports (Thompson et al.,
1994; Waters et al., 1996) have shown that Orf-A imposes a
small effect on FIV LTR-directed gene expression and is a
significantly weaker viral transactivator compared with
HIV-1 Tat. Interestingly, Vpr has also been shown to encode
an NLS (Sherman et al., 2001) and to enhance HIV-1 LTR-
driven gene expression by 5- to 20-fold (Goh et al., 1998;
Wang et al., 1995). Also of note, the magnitude of enhance-
ment of viral gene expression observed with Vpr is com-
parable to that previously reported for FIV Orf-A (Chatterji
et al., 2002; Sparger et al., 1992; Thompson et al., 1994;
Waters et al., 1996). These similarities described thus far
suggest that Orf-A expresses properties and functions sim-
ilar to Vpr encoded by HIV-1.
Another primary function described for HIV-1 Vpr
includes induction of cell cycle arrest at G2 of the cell cycle
(Jowett et al., 1995; Rogel et al., 1995). Thus far, Orf-A
expresses two properties previously assigned to HIV-1 Vpr,
that is, nuclear localization and enhancement of LTR-direct-
ed viral gene expression. This study now describes another
property, specifically induction of cell cycle arrest, that is
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profiles of COS-7 cells transiently expressing GFP-Orf-A
revealed an increased (4.8-fold) proportion of cells arrested
in G2 of the cell cycle compared to cells expressing GFP
alone (Fig. 4). This effect of Orf-A imposed on cell cycle is
very similar to that measured for HIV-1 Vpr in previous
studies describing Vpr-induced G2 arrest in COS cells
(Jowett et al., 1995). Consistent with our observations,
CAEV Tat that shares homology with FIV Orf-A has also
been shown to localize to the nucleus and arrest cells in G2
(Villet et al., 2003). In the present study, we also demon-
strate that a truncated form of Orf-A expressed as the N-
terminal half of the protein (GFP-Orf-Atrp43stop) induced a
smaller (1.7-fold) shift of cells to the G2 phase of the cell
cycle (Fig. 4). These findings suggest that putative domains
or regions located in the N terminus of Orf-A may contrib-
ute to cell cycle arrest but that the N terminus of Orf-A is
not sufficient to induce cell cycle arrest comparable to that
observed with full-length Orf-A. Assessment for induction
of G2 arrest in feline lymphoid cell lines by native Orf-A
and additional Orf-A mutants in the context of other FIV
viral proteins will be required to fully characterize this Orf-
A-associated function.
HIV-1-encoded nuclear proteins including Rev and Vpr
also encode a nuclear export signal that is required for the
nuclear export of these proteins and is characterized by a
hydrophobic leucine-rich domain (Pollard and Malim, 1998;
Sherman et al., 2001). In a previous study, we demonstrated
that a leucine-rich domain encoded within Orf-A was
important for efficient viral replication and specifically for
virus infectivity (Gemeniano et al., 2003). To further ex-
plore similarities shared by HIV-1 Vpr with FIV Orf-A, an
amino acid comparison of these proteins was performed and
a partial alignment is shown in Fig. 1B. Interestingly, this
alignment reveals strong homology shared by the Orf-A
leucine-rich domain (34LIRLLQGLL42) and the second
leucine-rich helix of HIV-1 Vpr (60IIRILQQLL68) contain-
ing a NES (64LQQLL68) (Sherman et al., 2001). Our current
findings also demonstrate that the GFP-Orf-A-L-A mutant
protein localized to the nucleus as predicted. However,
future studies directly testing for nuclear export properties
of Orf-A and the Orf-A-L-A mutant will be necessary to
verify that Orf-A is a nucleocytoplasmic shuttling protein
similar to HIV-1 Vpr and that the leucine-rich domain
within Orf-A is critical for this activity.
Thus far, findings from our current study reveal that Orf-
A of FIV shares two properties with HIV-1 Vpr including
nuclear localization and G2 arrest. A third similarity is a
possible NES that is highly conserved between HIV-1 Vpr
and FIV Orf-A. Furthermore, modest enhancement of FIV
LTR-directed gene expression previously described for FIV
Orf-A is very similar to the activity previously reported for
HIV-1 Vpr transactivation of the HIV-1 LTR. These simi-
larities between FIV Orf-A and HIV-1 Vpr have not been
previously reported or recognized, yet emphasize the con-
servation of specific viral functions between the feline andprimate immunodeficiency-inducing lentiviruses. However,
these findings do not preclude the possibility that Orf-A
may express functions encoded by other HIV proteins.
Previously, we have shown that Orf-A is important in the
late steps involved in viral particle formation, a function
shared with HIV-1-encoded Vpu and Nef, as well as Vpr.
Previous reports have provided conflicting evidence as to
the requirement of Orf-A for FIV replication in macro-
phages (Dean et al., 1999; Pistello et al., 2002; Waters et
al., 1996), whereas HIV-1 Vpr expression is crucial for HIV
infection of macrophages (Heinzinger et al., 1994). It is
highly possible that FIV Orf-A may encode specific func-
tions from several different HIV-1-encoded accessory but
not all functions characterized for a single HIV-1 accessory
protein. Future studies that include the characterization of
specific FIV Orf-A domains important for G2 arrest and
assessment of Orf-A for other HIV-1 accessory gene (in-
cluding Vpr) properties will further define mechanisms by
which unique species-specific lentiviruses encode similar
viral functional and pathogenic determinants.Materials and methods
Plasmid construction
Complete and partial sequences of the orf-A gene (Fig. 1)
were cloned into pEGFP-C1 (Clontech Laboratories, Palo
Alto, CA), a commercial plasmid for expression of proteins
fused to the C terminus of the green fluorescent protein (GFP)
for transient expression and subcellular localization studies.
First, full-length orf-A was PCR-amplified from wild-type
(WT) FIV-pPPR-based provirus plasmid, pSVWT (Bigornia
et al., 2001) using oligonucleotides, BamHIorfAs (CGCGG-
ACCATGGAAGTAATACGGATATTTAATAAGG), and
OrfALstop (ACGCGTC GACCTAAGCAGTATCTATG-
GATAATGTAG), and then cloned into pEGFP-C1 to create
GFP-Orf-A fusion expression plasmid, pEGFP-Orf-A, as
previously described (Gemeniano et al., 2003). Using the
same PCR primers and cloning approach, point mutants of
orf-A were PCR-amplified from orf-A mutant proviruses
previously described (Gemeniano et al., 2003) and cloned
into pEGFP-C1 to create pEGFP-Orf-A-trp43stop and
pEGFP-Orf-A-L-A. Mutant orf-A encoded by pEGFP-Orf-
A-trp43stop is characterized by replacement of amino acid
residue W43 with a stop codon, whereas pEGFP-Orf-A-L-A
includes an orf-A gene mutant encoding alanine substitutions
for leucine residues 34, 37, 38, 41, and 42 (Fig. 1). Oligonu-
cleotides, OrfAU6118 (GAAGATCTTGGAGACTGA-
GATTTAGAAAACC), and OrfALstop were used to PCR
amplify a 108-bp fragment spanning nt 6118–6225 from
FIV-pPPR to create pEGFP-Orf-A43–77 for expression of an
Orf-A deletion mutant encoding residues 43–77. A 75-bp
fragment spanning nt 6151–6225 was PCR amplified from
WT FIV-pPPR with primers OrfAU6152 (GAAGATCT-
GATTGTTTATGTTGGTTTTGCTGC) and OrfALstop and
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A54–77 for expression of the C-terminal residues 54–77
of Orf-A. Sequences of all GFP-Orf-A constructs were
confirmed by automated DNA sequencing.
Fluorescence microscopy
Before transfection, COS-7 cells were plated at 50–80%
confluency in a 25 cm2 flask in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% heat-inactivated
fetal bovine serum (FBS) and transfected the following day
with 1 Ag of expression plasmid DNA using Fugene lip-
ofection reagent (Roche Molecular Biochemicals, RMB,
Indianapolis, IN) according to the manufacturer’s instruc-
tions. Crandell feline kidney (CrFK) cells, a feline adherent
cell line (ATCC CCL 94) cultivated as previously described
(Bigornia et al., 2001), were plated at 50% confluency in a
175 cm2 flask and transfected by electroporation the next
day with 10 Ag of expression plasmid DNA as previously
described (Bigornia et al., 2001). Twenty-four hours post-
transfection, cells were plated on 8-well Permanox cham-
bered slides (Nunc, Naperville, IL) at a concentration of 105
cells/well. The next day, cells were washed twice with
phosphate-buffered saline (PBS), fixed by incubation with
4% paraformaldehyde/PBS for 30 min at room temperature,
and permeabilized with 0.5% Tween/PBS. Cells were incu-
bated with Vectasheild mounting medium for fluorescence
with nuclear stain 4V,6V-diamidino-2-phenylindole (DAPI)
(Vector Laboratories Inc., Burlingame, CA). Localization
was determined by GFP and DAPI fluorescence detected
with the Nikon Eclipse E800 microscope.
Immunoblot
COS-7 cells were either mock transfected or transfected
with pEGFP-C1, pEGFP-Orf-A, pEGFP-Orf-A-L-A,
pEGFP-Orf-Atrp43stop, pEGFP-Orf-A43–77, and pEGFP-
Orf-A54–77 using Fugene lipofection reagent (Roche Mo-
lecular Biochemicals, RMB) according to the manufactur-
er’s instructions. Forty-eight hours post-transfection, cells
were harvested and lysed in RIPA buffer (50 mM Tris–HCl,
pH 8.0, 1.0% NP40, 0.25% Na-deoxycholate, 150 mM
NaCl, 1 mM EDTA, 1 mM PMSF, 5 Ag/ml aprotinin, 50
Ag/ml leupeptin, 1 mM Na3VO4, 1 mM NaF). GFP-Orf-A
fusion proteins were immunoprecipitated from cell extracts
with mouse monoclonal anti-GFP antibody (JL-8, Clontech
Laboratories) using protocols previously described (Sawai
et al., 1996), separated on a 12% SDS-PAGE, transferred
onto a nitrocellulose membrane, and analyzed for GFP-Orf-
A proteins by Western blot analysis using the same anti-
GFP antibody or by using a polyclonal FIV Orf-A-specific
antibody. This Orf-A-specific antibody was harvested from
rabbits inoculated with recombinant Orf-A produced from a
bacterial expression vector (pQE-30; Qiagen Inc., Valencia,
CA) encoding FIV-pPPR Orf-A. Protein bands were visu-
alized by use of Supersignal West Dura Extended DurationSubstrate (Pierce, Rockford, IL) and exposure of the nitro-
cellulose to X-ray film.
FACS analysis of cell cycle
COS-7 cells (4  105) were plated in 75 cm2 flasks and
transfected the next day with 3 Ag of either pEGFP-Orf-A,
pEGFP-Orf-Atrp43stop, or pEGFP-C1 (negative control)
using Fugene lipofection reagent. After transfection, cells
were cultured for 40 h at 37 jC and then incubated with 50
AM BrdU (BD PharMingen, Chicago, IL) for the final 2 h of
the culture period. Cells were next harvested from flasks
using cold 5 mM EDTA/PBS, washed twice in PBS/BSA
solution, fixed, and permeabilized using the BrdU Flow kit
(BD PharMingen) according to manufacturer’s instructions.
DNA of fixed and permeabilized cells was digested with
300 Ag/ml DNase I (Sigma, St. Louis, MO) for 1 h at 37 jC.
BrdU-treated cells were incubated with anti-BrdU-PE-la-
beled antibody for 45 min, stained with 7-amino actinomy-
cin D (7AAD), and analyzed for fluorescence by FACScan
using the CellQuest program (Becton Dickinson, San Jose,
CA). Data for each sample were normalized for cell number
and then analyzed. After gating out cellular aggregates and
debris, cell cycle distribution was determined based on the
BrDU and 7AAD incorporation of the green fluorescent
population only.Acknowledgments
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